首页> 外文期刊>Journal of Medicinal Chemistry >Development of Novel N-hydroxypyridone Derivatives as Potential Anti-Ischemic Stroke Agents
【24h】

Development of Novel N-hydroxypyridone Derivatives as Potential Anti-Ischemic Stroke Agents

机译:开发新型N-羟基吡啶衍生物作为潜在的抗缺血性卒中剂

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Our previous study had identified ciclopirox (CPX) as a promising lead compound for treatment of ischemic stroke. To find better neuroprotective agents, a series of N-hydroxypyridone derivatives based on CPX were designed, synthesized, and evaluated in this study. Among these derivatives, compound 11 exhibits significant neuroprotection against oxygen glucose deprivation and oxidative stress -induced injuries in neuronal cells. Moreover, compound 11 possesses good blood-brain barrier permeability and superior antioxidant capability. In addition, a complex of compound 11 with olamine-11.01a possesses good water solubility, negligible hERG inhibition, and superior metabolic stability. The in vivo experiment demonstrates that 11.01a significantly reduces brain infarction and alleviates neurological deficits in middle cerebral artery occlusion rats. Hence, compound 11.01a is identified in our research as a prospective prototype in the innovation of stroke treatment.
机译:我们以前的研究鉴定了Ciclopirox(CPX)作为用于治疗缺血性卒中的有前途的铅化合物。 为了寻找更好的神经保护剂,设计了一系列基于CPX的N-羟基吡啶衍生物,在本研究中设计,合成和评估。 在这些衍生物中,化合物11对神经元细胞的氧血糖剥夺和氧化应激损伤表现出显着的神经保护作用。 此外,化合物11具有良好的血脑屏障渗透性和优异的抗氧化能力。 另外,具有奥拉莫宁-11.01A的化合物11的复合物具有良好的水溶性,忽略不计的药物抑制和优异的代谢稳定性。 体内实验表明,11.01A显着降低了脑梗塞,并减轻了中脑动脉闭塞大鼠中的神经缺陷。 因此,在我们的研究中确定了化合物11.01A作为中风治疗创新的前瞻性原型。

著录项

  • 来源
    《Journal of Medicinal Chemistry》 |2020年第3期|共17页
  • 作者单位

    East China Univ Sci &

    Technol Sch Pharm State Key Lab Bioreactor Engn Shanghai 200237 Peoples R China;

    Chinese Acad Sci Shanghai Inst Mat Med CAS Key Lab Receptor Res Shanghai 201203 Peoples R China;

    Chinese Acad Sci Shanghai Inst Mat Med CAS Key Lab Receptor Res Shanghai 201203 Peoples R China;

    Chinese Acad Sci Shanghai Inst Mat Med Shanghai 201203 Peoples R China;

    Chinese Acad Sci Shanghai Inst Mat Med CAS Key Lab Receptor Res Shanghai 201203 Peoples R China;

    Chinese Acad Sci Shanghai Inst Mat Med CAS Key Lab Receptor Res Shanghai 201203 Peoples R China;

    Chinese Acad Sci Shanghai Inst Mat Med CAS Key Lab Receptor Res Shanghai 201203 Peoples R China;

    Chinese Acad Sci Shanghai Inst Mat Med CAS Key Lab Receptor Res Shanghai 201203 Peoples R China;

    East China Univ Sci &

    Technol Sch Pharm Shanghai Key Lab New Drug Design Shanghai 200237 Peoples R China;

    East China Univ Sci &

    Technol Sch Pharm State Key Lab Bioreactor Engn Shanghai 200237 Peoples R China;

    East China Univ Sci &

    Technol Sch Pharm State Key Lab Bioreactor Engn Shanghai 200237 Peoples R China;

    East China Univ Sci &

    Technol Sch Pharm Shanghai Key Lab New Drug Design Shanghai 200237 Peoples R China;

    East China Univ Sci &

    Technol Sch Pharm State Key Lab Bioreactor Engn Shanghai 200237 Peoples R China;

    East China Univ Sci &

    Technol Sch Pharm Shanghai Key Lab New Drug Design Shanghai 200237 Peoples R China;

    East China Univ Sci &

    Technol Sch Pharm State Key Lab Bioreactor Engn Shanghai 200237 Peoples R China;

    Chinese Acad Sci Shanghai Inst Mat Med Shanghai 201203 Peoples R China;

    Chinese Acad Sci Shanghai Inst Mat Med CAS Key Lab Receptor Res Shanghai 201203 Peoples R China;

    East China Univ Sci &

    Technol Sch Pharm State Key Lab Bioreactor Engn Shanghai 200237 Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号